Entity family
Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.
Showing 4,741–4,800 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.
…74T, SW480, T84), as well as a CD87-negative control cell line (HEK293). To further optimize CAR design, we employed a Jurkat NFAT-Luc…
…t cancer cells compared to conventional CAR-T cells. In the AML NSG mouse model, HCW11-006-treated mice exhibited enhanced tumor clearance and …
…sposon or CRISPR/Cas systems.Acknowledgements Data generated by MaxCyte Technical Applications Lab or in collaboration with CIMA/Clinica Universidad de Navarra an…
…ntly in the last stages of review for DDT qualification through FDA’s ISTAND program.…
… translational relevance.Methods To overcome these limitations, Champions Oncology and Taconic Biosciences developed a humanized in vivo AML platf…
…ial in MRCLS (CT.gov, NCT02992743) Lete-cel phase 2 IGNYTE-ESO (CT.gov NCT03391778)Ethics Approval This was a secondary analysis of ex…
…ets collection) were obtained from healthy volunteers under the Roswell Park Comprehensive Cancer Center (RPCCC) Institutional Review Board (IRB)-approved protocol 1632…
…s study was approved by the Investigational Review Board at the National Cancer Institute (NCI) in accordance with an assurance filed with and approved b…
…) IRB-approved protocol 11-181. A cohort of patients treated at Massachusetts General Hospital was processed, isolated, and in vitro expanded for generating p…
…phoma, and myeloma.Methods MEDLINE, Embase, Web of Science, and Cochrane CENTRAL databases were searched. SPM cases were extracted, malignancies…
…022 and Protocol IRSTB137, cod. L3P2767, Approval date from the Romagna Ethics Committee (CEROM) 14/03/2024) and the study was conducted in accordance w…
…th metastatic biliary tract cancer: a randomized phase 2 study. Clinical Cancer Research. 2024 Aug 15;30(16):3428–37.Abstract 41 Figure 1Pharmacodynamic…